PDS Biotechnology (NASDAQ:PDSB – Get Free Report) and Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Risk and Volatility
PDS Biotechnology has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.
Earnings and Valuation
This table compares PDS Biotechnology and Lipella Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PDS Biotechnology | N/A | N/A | -$42.94 million | ($1.16) | -1.23 |
| Lipella Pharmaceuticals | $450,000.00 | 7.85 | -$4.62 million | ($4.25) | -0.69 |
Institutional & Insider Ownership
26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 9.5% of PDS Biotechnology shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares PDS Biotechnology and Lipella Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PDS Biotechnology | N/A | -139.57% | -67.22% |
| Lipella Pharmaceuticals | -882.82% | -192.33% | -154.24% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for PDS Biotechnology and Lipella Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PDS Biotechnology | 0 | 0 | 3 | 1 | 3.25 |
| Lipella Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
PDS Biotechnology presently has a consensus target price of $11.67, suggesting a potential upside of 715.85%. Lipella Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 447.95%. Given PDS Biotechnology’s stronger consensus rating and higher possible upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Lipella Pharmaceuticals.
Summary
PDS Biotechnology beats Lipella Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
